Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

Erstveröffentlichung
2009Authors
Zenz, Thorsten
Haebe, Sonja
Denzel, Tina
Mohr, Julia
Winkler, Dirk
Wissenschaftlicher Artikel
Published in
Blood ; 114 (2009), 13. - S. 2589-2597. - ISSN 0006-4971
Link to publication
https://dx.doi.org/10.1182/blood-2009-05-224071Institutions
UKU. Klinik für Innere Medizin IIISubject headings
[Free subject headings]: joining dna-repair | phase-3 trial | plus cyclophosphamide | cytogenetic analysis | genomic aberrations | 1st-line therapy | drug-resistance | cd38 expression | gene-expression | b-cells[DDC subject group]: DDC 610 / Medicine & health